VCs Back DVS Sciences With $14.6M

A group of investors including 5AM Ventures, Pfizer Venture Investments, Mohr Davidow, the Roche Venture Fund and the Ontario Institute for Cancer Research have put $14.6 million into DVS Sciences Inc. With offices in Ontario and Sunnyvale, Calif., DVS Sciences is a manufacturer of highly multi-parameter single-cell analyzers and reagents for biological research and clinical applications. The company will use the Series A financing to expand its commercial manufacturing efforts.

VirtuOz Nabs $7M

VirtuOz Inc. has raised $7 million in financing from existing backers Mohr Davidow, Inventures Group and Galileo Partners. The money is aimed at fueling growth for VirtuOz, which develops “intelligent virtual agents” for use in online customer service. The Redwood City, Calif.-based company closed an $11.4 million Series B round in 2009.

Paul Cleveland Joins Mohr Davidow

Early stage venture firm Mohr Davidow has added Paul Cleveland as a general partner and as chief operating officer. Cleveland joins from Affymax, a pharmaceutical company, where he was chief financial officer and executive vice president of corporate development. In his new role, Cleveland will be responsible for all finance, operations and administrative functions at Mohr Davidow, the firm said in a statement.

Fliqz Investors Take a Bath

Fliqz’s investors took a loss when the California-based plug-and-play video solution provider was sold in a private foreclosure to video streaming company VBrick earlier this month, multiple sources confirmed to Two sources confirmed the company was sold for less than its three rounds of funding. One of the sources acknowledged the sale process, run […]

Mark Tsimelzon Joins Mohr Davidow Ventures

Mark Tsimelzon has joined Mohr Davidow Ventures as an entrepreneur-in-residence, according to his LinkedIn profile. He previously served as director of engineering for Hadoop and cloud computing at Yahoo, and before that was founder or Coral8 (acquired by Sybase).

Venture Capitalist Named Navigenics CEO

Vance Vanier has joined personalized genomics company Navigenics as president and CEO. He previously was a partner with Navigenics investor Mohr Davidow Ventures. Navigenics has raised over $25 million in VC funding, from MDV, Kleiner Perkins and Sequoia Capital.

VCs Compete Hard For Early-Stage Science Projects

Mohr Davidow this month named four researchers — two from Stanford and two from UC Berkeley — as recipients of a new Innovators Award that the venture firm designed last year. Each researcher will get $50,000, which Mohr Davidow’s partners are taking out of their own fees, to work for a year on a high-risk project. Researchers are picked by senior faculty at their schools and can’t be tenured.

“This program is designed to identify, award and accelerate the early careers of professors we think have high potential for research and commercialization,” said MDV partner Erik Straser.

All four winners — assistant professors Nick Melosh and Thomas Jaramillo at Stanford, UC Berkeley assistant professor Ali Javey, and Delia Milliron, who works at Lawrence Berkeley National Laboratory — are pursuing projects that may have applications to clean tech, including new ways to capture solar energy and make buildings more energy efficient.

One of last year’s winners, assistant professor Yi Cui of Stanford, who specializes in nanotechnology, said he is talking to Mohr Davidow about forming a company

MDV Caps 3 Annex Funds, Raises Total of $127M

Four months of fund-raising helped Mohr Davidow Ventures raise an extra $29.2 million for three annex funds, according to documents filed with the SEC today.

MDV’s effort to raise the annex funds first came to light in August, when it filed SEC documents showing that it had raised a combined $98.1 million in annex funds for its seventh, eighth and ninth core funds. Today’s updated filings show that the grand total increased to $127.3 million.

The fund IX annex fund faired the best from the additional effort. It boosted its total to $72.1 million, up from $45.3 million on Aug. 7. The Dec. 3 filing indicates that’s a final close, as the line for “total remaining to be sold” says zero.

The fund VIII annex fund also got a bit of a boost. It held a final close on $27.9 million, according to the Dec. 3 filing, up from $25.5 in August.

The firm’s seventh fund did not (or could not) raise any additional capital since August. It held a final close on $27.3 million.

Combining Portfolio Companies To Save Them

This week I reported that Mohr Davidow had combined two of its cancer-fighting biotech startups — CELLective Diagnostics and The DNA Repair Company — into a third, new company called On-Q-ity.

Last month I reported that, a Draper Fisher-funded service to share and store content online, had purchased another Draper, Fisher-backed company — Increo.

It turns out that this is a trend. Mohr Davidow’s Sue Siegel said she knew of two other venture firms that are talking about ways to combine each other’s portfolio companies, and a glance through the tech blogs of the last couple months shows that Softbank Capital and angel investor Ron Conway may be doing the same.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget